procarbazine has been researched along with Gliosarcoma in 1 studies
Procarbazine: An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease.
procarbazine : A benzamide obtained by formal condensation of the carboxy group of 4-[(2-methylhydrazino)methyl]benzoic acid with the amino group of isopropylamine. An antineoplastic chemotherapy drug used for treatment of Hodgkin's lymphoma. Metabolism yields azo-procarbazine and hydrogen peroxide, which results in the breaking of DNA strands.
Gliosarcoma: Rare mixed tumors of the brain and rarely the spinal cord which contain malignant neuroectodermal (glial) and mesenchymal components, including spindle-shaped fibrosarcoma cells. These tumors are highly aggressive and present primarily in adults as rapidly expanding mass lesions. They may arise in tissue that has been previously irradiated. (From Br J Neurosurg 1995 Apr;9(2):171-8)
Excerpt | Relevance | Reference |
---|---|---|
"A randomized, multicentre, open-label, phase II study compared temozolomide (TMZ), an oral second-generation alkylating agent, and procarbazine (PCB) in 225 patients with glioblastoma multiforme at first relapse." | 9.09 | A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. ( Albright, RE; Brada, M; Bruner, J; Fink, K; Fredericks, R; Friedman, H; Glantz, M; Greenberg, H; Hohl, RJ; Levin, VA; Olson, J; Osoba, D; Phillips, P; Prados, MD; Rampling, R; Selker, RG; Shapiro, W; Spence, A; Vick, NA; Yue, N; Yung, WK; Zaknoen, S, 2000) |
"A randomized, multicentre, open-label, phase II study compared temozolomide (TMZ), an oral second-generation alkylating agent, and procarbazine (PCB) in 225 patients with glioblastoma multiforme at first relapse." | 5.09 | A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. ( Albright, RE; Brada, M; Bruner, J; Fink, K; Fredericks, R; Friedman, H; Glantz, M; Greenberg, H; Hohl, RJ; Levin, VA; Olson, J; Osoba, D; Phillips, P; Prados, MD; Rampling, R; Selker, RG; Shapiro, W; Spence, A; Vick, NA; Yue, N; Yung, WK; Zaknoen, S, 2000) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Yung, WK | 1 |
Albright, RE | 1 |
Olson, J | 1 |
Fredericks, R | 1 |
Fink, K | 1 |
Prados, MD | 1 |
Brada, M | 1 |
Spence, A | 1 |
Hohl, RJ | 1 |
Shapiro, W | 1 |
Glantz, M | 1 |
Greenberg, H | 1 |
Selker, RG | 1 |
Vick, NA | 1 |
Rampling, R | 1 |
Friedman, H | 1 |
Phillips, P | 1 |
Bruner, J | 1 |
Yue, N | 1 |
Osoba, D | 1 |
Zaknoen, S | 1 |
Levin, VA | 1 |
1 trial available for procarbazine and Gliosarcoma
Article | Year |
---|---|
A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; | 2000 |